Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. In 2010 update, IDSA recommended Piperacillin/tazobactam as first-line mono-therapy for febrile patients with neutropenia of high risk. In china, the data of piperacillin/tazobactam for febrile neutropenia after hematopoietic stem cell transplantation is very limited.

The current study will evaluate the efficacy of piperacillin/tazobactam compared with imipenem/cilastatin for febrile neutropenia after transplantation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Treatments: Imipenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

Criteria

Inclusion Criteria:

• Age 13-65 years

• received Autologous or Allogeneic hematopoietic stem cell transplantation.

• ECOG score 0-1.

• ICF is available.

Exclusion Criteria:

• Allergic to any therapy drug.

• Documented infection before neutropenia.

• Renal dysfunction.

• Suffering from central nervous system or mental disease.